AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03775252 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Diet rich in fats and poor in carbohydrate, to induce metabolic ketosis
Study NCT03068312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: IVA 150 mg tablet.
Study NCT03068312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to IVA tablet.
Study NCT01852045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the detrusor wall on Day 1.
Study NCT03146780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Scan 3
Description: Direct intra-oral digital scans using 3M True Definition software.
Study NCT01828138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sodium
Description: supplemental sodium tablets 150-200 mmol/day in 5 days
Study NCT01828138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Placebo are given in 5 days
Study NCT00394563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00693004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-03140
Study NCT00693004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Study NCT00536458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: mini chep+ radiotherapy
Study NCT00536458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MINI CHEP
Description: chemotherapy minichep 6 courses
Study NCT01521260 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
Study NCT00693004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04103463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive stepping exercise
Description: An exercise intervention based on the principle of square stepping exercise
Study NCT04103463 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Home exercise
Study NCT04668924 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epi-on PiXL in high oxygen
Description: After local anaesthetics, the keratoconus cornea is soaked in Riboflavin by repeated topical application during 10 minutes. A Riboflavin soaked sponge is used to lightly disrupt the epithelium tight junctions, without epithelium debridement. The cornea is illuminated with PiXL under 16:40 minutes during continuously delivery of humidified high oxygen via specific oxygen googles. The UV-dosage is individually customized based upon Kmax; for \< 45 Diopters (D) 7.2J/cm\^2 will be used; for 45-50D 10J/cm\^2 will be used; for > 50D 15 J/cm\^2 will be used.
Study NCT01853072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac Ophthalmic Suspension, 0.3%
Description: Test intervention
Study NCT01853072 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac vehicle
Description: Inactive ingredients used as placebo comparator
Study NCT01853072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Study NCT01853072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone acetate
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Study NCT02544334 — intervention group
Intervention type: PROCEDURE
Intervention: Dental Plaque
Description: All participants will have dental plaque removed from different tooth surfaces for supragingival.
Study NCT02544334 — intervention group
Intervention type: OTHER
Intervention: Multi-dimensional health assessment questionnaire (MDHAQ)
Description: The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
Study NCT01521260 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
Study NCT03245827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: clomiphene capsule 25mg twice a week
Study NCT03245827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule 25mg twice a week
Study NCT02544334 — intervention group
Intervention type: OTHER
Intervention: Saliva Collection
Description: All participants will have a saliva collection.
Study NCT02971020 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observational/Cognitive Assessment
Description: Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
Study NCT01284361 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 cm Intermittent Catheter
Description: Randomized cross-over
Study NCT01284361 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 40 cm Intermittent Catheter
Description: randomized cross-over
Study NCT06522217 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasoalveolar molding appliance
Description: making impression then make the conventional lab procedures for group A for the production of conventional appliances
Study NCT06522217 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: digital nasoalveolar molding appliance
Description: group B scanning the model and designing the appliances on 3shap and 3d printing the appliances
Study NCT01528007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone pharmacotherapy
Description: Naltrexone 50mg when graving to gamble.
Study NCT01528007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill with no active ingredients.
Study NCT01527383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ
Study NCT01527383 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator to V212 vaccine
Study NCT00746733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Description: 50mg capsule
Study NCT00746733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall XR (mixed salts amphetamine)
Description: 20mg capsule
Study NCT01497808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT03358641 — intervention group
Intervention type: OTHER
Intervention: level of physical activity
Description: According to the result of IPA-Q questionnaire, participants are divided in three groups: low level, moderate level, high level of physical activity.
Study NCT00849875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapeutic GSK2132231A
Description: Intramuscular administration
Study NCT00849875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Intravenous administration Chemotherapy
Study NCT02089152 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: An educational programme for prevention of melioidosis
Description: The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
Study NCT01497808 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Study NCT04686617 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Vibration
Description: Oral B HummingBird device (Procter\&Gamble, USA) with a modified tip was used for the application of vibration. The tip was positioned mid-buccally of teeth to perform buccally directed vibration. HummingBird is prescribed maximum period 0.00885s corresponding to 6800RPM or 113Hz of the motor. The vibration procedure was applied for 10mins/day during the period of 12 weeks.
Study NCT02827201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI.3
Description: For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)
Study NCT02827201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel+ gemcitabine
Description: For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.
Study NCT02827201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel+ gemcitabine
Description: For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.
Study NCT03111771 — intervention group
Intervention type: PROCEDURE
Intervention: carcinological surgery
Description: carcinological surgery for Group K +
Study NCT05794594 — intervention group
Intervention type: DEVICE
Intervention: 3D printed personalized extendable prosthesis
Description: 3D printed personalized extendable prosthesis replacement for limb preservation in children
Study NCT03918005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low glycemic load diet
Description: Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
Study NCT03918005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycemic load diet
Description: Foods with low glycemic index or glycemic load (brown rice, brown bread, whole wheat pasta, oat bran, yogurt, milk, apple, pear, peach)
Study NCT02773862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Study NCT03894384 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Trefoil factor family 3 (TFF3),Pepsinogen 1(PG1)
Description: Diagnostic Test: A) CBC . B) FBG. C)KFT. D) LFT. A)CBC: Complete blood count. B)FBG: Fasting blood glucose. C)KFT: Kidney function tests. D)LFT: Liver function tests.
Study NCT02745717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
Study NCT02745717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: administration of ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) intravenously for 5 days
Study NCT02745717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord blood
Description: transfusion of one unit of at least 4/6 HLA loci matched cord blood.
Study NCT02745717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine Oral Product
Description: administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
Study NCT02745717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine Oral Product
Description: administration of cyclosporine A 5mg/kg orally, and maintain the trough serum concentration between 200ng/ml to 300ng/ml.
Study NCT00657150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg once daily
Study NCT00657150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: 220 mg once daily
Study NCT05226091 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Letter
Description: Selected GP practices currently registered with CPRD will receive correspondence by both email and mail informing them about the result of the PLEASANT study and advising them how to implement what has been learnt. Included in the mailing would be a suggested letter and SMS text.
Study NCT02973191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCAR015
Study NCT02805231 — intervention group
Intervention type: OTHER
Intervention: Vitamin D receptor polymorphic analysis
Study NCT02416700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: immediate implant surgery
Description: Surgery of dental implants in one side of the mouth.
Study NCT02416700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant surgery (Straumann®)
Description: Dental implant surgery in one of the sides of the mouth
Study NCT02192229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50.000 IU vitamin D3 (Biodal 50,000 IU)
Study NCT02192229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (to mimic Biodal 50,000 IU)
Description: Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
Study NCT01046227 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza A (H1N1) 2009 monovalent vaccine, inactivated
Description: Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
Study NCT04411537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Before neo-CRT: 2 cycles of PD-1 antibody, 240mg d1 q2w. After neo-CRT: 3 cycles of PD-1 antibody, 240mg d1 q2w.
Study NCT04411537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: During neo-CRT: 625mg/m2 bid Monday-Friday per week
Study NCT04411537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: During neo-CRT: 80mg/m2 qw (UGT1A1\*28 6/6) or 65mg/m2 qw (UGT1A1\*28 6/7)
Study NCT04411537 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Radiotherapy
Description: IMRT DT: 50Gy/25Fx
Study NCT00012363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1,000mg/m2, IV over 30 min, days 1 \& 8, q 21 days
Study NCT00012363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 100 mg/m2, IV over 90 min, days 1 \& 8, q 21days
Study NCT01697150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiAs Diabetes Assistant Wearable Artificial Pancreas Platform
Description: Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spatial Match Exercise
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Temporal Sequence Reconstruction Exercise
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Token Task Exercise
Study NCT02223949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook double balloon catheter
Study NCT02223949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PGE1 tablet
Study NCT02404038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nur-Isterate
Description: Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Story Recall Exercise
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sample-Match (Within Modality) Exercise
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pair-Match (Across-Modality) Exercise
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Triad-FiguresExercise
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monster Garden Exercise
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Match Exercise
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Matrix Exercise
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familiar Faces Exercises
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lost in Migration Exercise
Study NCT02726191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Playing Koi Exercise
Study NCT02302183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeO2 v2.0 automatic adjustment
Study NCT02302183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeO2 v2.0 data collecting
Study NCT02068118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telecardiology program
Description: The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.~Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure.
Study NCT02884375 — intervention group
Intervention type: OTHER
Intervention: Extensive GA
Description: GA includes an evaluation of nine domains according to international recommendations :~* functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))~* mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)~* nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )~* cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)~* mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))~* comorbidities (CIRS G)~* polypharmacy (number of medications)~* social environment (primary caregiver, support at home, friends , family, living alone)~* urinary and/or fecal incontinence
Study NCT04094233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot extract
Description: Ingestion of 600mg beetroot extract two hours before strength exercise (75% 1RM).
Study NCT04094233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ingestion of 600mg starch two hours before strength exercise (75% 1RM).
Study NCT00624780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 150-300 mg given twice a day
Study NCT00624780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam 3-4 mg given twice a day
Study NCT00624780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 450-600 mg given twice a day
Study NCT00624780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03816280 — intervention group
Intervention type: PROCEDURE
Intervention: Elective cardiopulmonary bypass (CPB)
Description: All groups undergo elective cardiopulmonary bypass (CPB)
Study NCT02404038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nuvaring
Description: Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
Study NCT02404038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triphasil
Description: Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle~Composition:~The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.~The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.~The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.~The seven red tablets are inert